Media headlines about Halyard Health (NYSE:HYH) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Halyard Health earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 46.0497902260184 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Zacks Investment Research Downgrades Halyard Health (HYH) to Hold (americanbankingnews.com)
- Brokerages Expect Halyard Health Inc (HYH) to Announce -$0.04 EPS (americanbankingnews.com)
- Halyard Health, Inc. (HYH) : Investors watching Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- Halyard Health, Inc. (HYH) ended its day with the change of 1.77% – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Halyard Health, Inc. (HYH) year to date performance remained at 1.78% – Nasdaq Fortune (press release) (nasdaqfortune.com)
Halyard Health stock opened at $46.16 on Friday. The company has a current ratio of 2.98, a quick ratio of 2.74 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $2,205.24, a P/E ratio of 27.64, a P/E/G ratio of 5.50 and a beta of 1.60. Halyard Health has a 12-month low of $35.24 and a 12-month high of $50.99.
HYH has been the subject of several research analyst reports. TheStreet upgraded Halyard Health from a “c+” rating to a “b” rating in a research note on Monday, December 4th. Zacks Investment Research upgraded Halyard Health from a “hold” rating to a “buy” rating and set a $53.00 price target for the company in a research report on Wednesday, December 6th. Finally, ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $49.33.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.